Venous Leg Ulcer
Conditions
Brief summary
Venous leg ulcers (VLUs) are a common wound with significant morbidity and cost, and suboptimal therapeutic options. VLUs result from chronic venous insufficiency, including venous reflux and post-thrombotic syndrome. VLU can take from months to years to heal, and 54-78% recur. Current therapies include wound, compression therapy, and medications. These treatments can increase the rate of healing, and reduce recurrence, however these therapies can be burdensome, painful, and ineffective, and despite these therapies, \ 50% of wounds become chronic. Chronic VLUs can be painful, malodorous, and infected, and they often significantly limit an individual's function and mobility. An emerging therapy for symptomatic venous reflux is the closure of the culprit vein by endovenous closure with a cyanoacrylate adhesive implant. Recent studies show cyanoacrylate closure (CAC) to be a safe and effective treatment for varicosities resulting from symptomatic incompetent great saphenous veins. This study will evaluate the safety and effectiveness of CAC for VLUs.
Interventions
PROCEDURECyanoacrylate closure
Cyanoacrylate glue embolization targeting venous insufficiency
Sponsors
Medtronic Vascular
Sunnybrook Health Sciences Centre
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years old at time of screening; 2. Venous leg ulcer; 3. Venous insufficiency (\>0.5 seconds; confirmed by Doppler within last 6 months); 4. ABI of ≥0.9; 5. Capable of understanding the study and providing informed consent.
Exclusion criteria
1. Previous hypersensitivity reactions to the VenaSealTM adhesive or cyanoacrylates; 2. Acute superficial thrombophlebitis; 3. Bilateral treatment 4. Thrombophlebitis migrans; 5. Deep venous thrombosis; 6. Deep venous incompetence or occlusion in external iliac or distal veins in the affected extremity (as assessed based on spontaneity, phasicity, augmentation, pulsatility, and compressibility on ultrasound); 7. Post-thrombotic syndrome; 8. Acute sepsis; 9. Coagulation disorders; 10. Radiation or chemotherapy within 3 months of study; 11. Pregnant or lactating females; 12. Uncontrolled diabetes (HbA1c \>10%); 13. Diabetic foot ulcers; 14. Current use of systemic anticoagulation; 15. Previous treatment of target vein; 16. Tortuous veins; 17. Current participation in another interventional study, or participation within 30 days prior to screening; 18. Inability to tolerate compression, or to receive endovenous treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of adverse events | 3 months | — |
| Healing rate | 3 months | Change in ulcer size |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of adverse events | 12 months | — |
| Healing rate | 12 months | Change in ulcer size |
| Closure rate | 12 months | Time to ulcer closure |
| Patient-reported quality of life: EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire | 12 months | EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire - measures patient-reported health related to five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses for each parameter are coded 1-5, with a lower score reflecting better health, and a higher score meaning worse health. Overall health is self-rated on a scale 0-100, with 0 meaning the worst and 100 meaning the best health imaginable. |
Countries
Canada
Outcome results
None listed